Modulation of human fibroblast activity by selected angiogenesis inhibitors.
Tenon's fibroblast (TF) bleb encapsulation is a common cause of filtering surgery failure. Various pharmacologic agents have been used in an attempt to inhibit this response. The effects of three angiogenesis inhibitors were studied. AGM-1470, a fumagillin analog and hydrocortisone 21-phosphate (HC21P) complexed with heparin or with the heparin analog beta-cyclodextrin tetradecasulfate (BCD-TDS) in modulating human tenon's fibroblasts in cell culture. It has been clinically demonstrated that well vascularized blebs are associated with a poorer prognosis. In addition to reducing bleb neovascularization, angiogenesis inhibitors may have an additional therapeutic role in decreasing fibroblast activity. Drug effects were assessed by studying cell growth rates by cell Coulter counting and rate of wound closure. TF's were grown in DMEM with 10% FBS and 1% PCN-strep with fungizone. Angiogenesis inhibitors were added to growth medium in varying concentrations: AGM-1470 alone, HC21P complexed with heparin and HC21P complexed with BCD-TDS. Controls were grown in control medium alone, medium with added ethanol, or with added BCD-TDS, heparin or HC21P. We found a dose related inhibition of cell growth with all of the angiogenesis inhibitor combinations, which was not seen in the control groups. Tenon's fibroblast proliferation was significantly inhibited by AGM-1470 as seen in the four higher concentrations (P < 0.05) with insignificant inhibition at the lowest concentration of AGM-1470 (P = 0.38). The heparin:HC21P and heparin:BCD-TDS combinations demonstrated significant inhibition at all concentrations (P < 0.05). Wound closure was significantly inhibited by all the added agents, except AGM-1470 and the controls. The rate of wound closure was significantly reduced by the highest concentrations of the heparin:HC21P and heparin:BCD-TDS combinations (P < 0.05), although it was not significantly affected by lower concentrations (P > 0.05). Rank order of potencies of these agents for inhibition of TF proliferation was AGM-1470, BCD-TDS:HC21P, heparin:HC21P, HC21P, while the rank order of potencies for these agents for inhibition of wound closure was HC21P, heparin:HC21P, BCD-TDS:HC21P, AGM-1470. These selected angiogenesis inhibitors appear to have marked inhibitory effects on TF proliferation and migration, which may have a potential clinical role in modulating wound healing associated with glaucoma filtering surgery.
Wong
J
J
New England Eye Center, New England Medical Center Hospitals, Tufts University School of Medicine, Boston, MA 02111.
Wang
N
N
Miller
J W
JW
Schuman
J S
JS
D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D003505:Cyclodextrins / Q000494:pharmacology*; D003510:Cyclohexanes; D004305:Dose-Response Relationship, Drug; D005123:Eye / Q000098:blood supply / Q000166:cytology*; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D005901:Glaucoma / Q000601:surgery; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives* / Q000494:pharmacology; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012717:Sesquiterpenes / Q000494:pharmacology*; D013997:Time Factors; D014945:Wound Healing / Q000187:drug effects; D047392:beta-Cyclodextrins
D003505:Cyclodextrins; D003510:Cyclohexanes; D012717:Sesquiterpenes; D047392:beta-Cyclodextrins; C039803:hydrocortisone sodium phosphate; C064089:beta-cyclodextrin tetradecasulfate; D006854:Hydrocortisone; D000077609:O-(Chloroacetylcarbamoyl)fumagillol